• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

社区成员和患者对与带状疱疹相关的临时健康状态的偏好为基础的 QALY 的支付意愿。

Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

机构信息

Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts 02215, USA.

出版信息

Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000.

DOI:10.2165/11314000-000000000-00000
PMID:19908925
Abstract

BACKGROUND AND OBJECTIVES

A clear sense of what society is willing to pay for a QALY could enhance the usefulness of cost-effectiveness analysis as a field. Scant information exists on willingness to pay (WTP) for a QALY based on direct elicitation of preferences from community members or patients. We had the opportunity to evaluate WTP per QALY using data from a survey on temporary health outcomes related to herpes zoster. Our aims were to (i) describe how much community members are willing to pay to save a QALY based on scenarios describing temporary health states; (ii) evaluate how WTP per QALY varies based on experience with the disease being described and with demographic variables; and (iii) evaluate how the duration and intensity of pain in a scenario influences WTP per QALY.

METHODS

Community members drawn from a nationally representative survey research panel (n = 478) completed an Internet-based survey using time trade-off (TTO) and WTP questions to value a series of scenarios that described herpes zoster cases of varying pain intensity (on a scale of 0-10) and duration (30 days to 1 year). Patients with shingles (n = 354) or postherpetic neuralgia (PHN; n = 120) [defined as having symptoms for 90 days or more] from two large healthcare systems completed telephone interviews with similar questions. Mean and median WTP per QALY values were calculated by dividing the WTP amount by the discounted time traded for each scenario. Responses with a WTP value of more than zero and a TTO value of zero (which would have resulted in an undefined value) were excluded. TTO values were discounted by 3% per year. WTP per QALY means were calculated after trimming the top and bottom 2.5% of responses. Multivariate analyses were conducted using generalized linear mixed models that assumed a negative binomial distribution.

RESULTS

Among all respondents, the WTP per QALY ranged from a median of $US7000 to $US11,000 and a trimmed mean of $US26 000 to $US45,000 (year 2005 values), depending on the scenario described. WTP per QALY values varied significantly with respondent characteristics, as well as among respondents with similar characteristics. In multivariate analyses, the mean WTP per QALY was higher among respondents who were younger, male or had higher educational or income levels. After adjusting for these demographic variables, patients who had experienced shingles gave responses with the highest WTP per QALY values. Patients who had experienced PHN gave the lowest values, and community members gave values intermediate to the shingles and PHN groups. In multivariate models that evaluated the effects of pain and duration of the hypothetical zoster scenario, lower duration was associated with higher WTP per QALY. This effect appeared to be due to people increasing the amounts of time they would be willing to trade as duration increased, without proportional increases in the amounts of money they would be willing to pay.

CONCLUSIONS

Community members and patients gave mean WTP per QALY values that varied significantly based on age, sex, socioeconomic status, experience with shingles and duration of the health state evaluated. The variability in WTP per QALY suggests that it may be difficult to define a unitary threshold of dollars per QALY for policy making based on cost-effectiveness analyses.

摘要

背景与目的

明确社会对 QALY 的支付意愿,可以提高成本效益分析作为一个领域的有用性。关于基于社区成员或患者偏好的直接 elicitation 的 QALY 的支付意愿(WTP)的信息很少。我们有机会使用与带状疱疹相关的临时健康结果调查的数据来评估每 QALY 的 WTP。我们的目的是:(i)描述社区成员基于描述临时健康状况的情景愿意支付多少来挽救一个 QALY;(ii)评估基于描述的疾病的经验和人口统计学变量的每 QALY 的 WTP 如何变化;(iii)评估情景中疼痛的持续时间和强度如何影响每 QALY 的 WTP。

方法

从全国代表性的调查研究小组中抽取的社区成员(n=478)通过互联网完成了一项基于时间权衡(TTO)和 WTP 的调查,以评估一系列描述不同疼痛强度(0-10 分)和持续时间(30 天至 1 年)的带状疱疹病例的情景。来自两个大型医疗保健系统的带状疱疹(n=354)或带状疱疹后神经痛(PHN;n=120)[定义为症状持续 90 天或更长时间]的患者通过类似的问题进行了电话访谈。通过将 WTP 金额除以每个情景的贴现时间,计算出每 QALY 的平均和中位数 WTP 值。排除 WTP 值大于零且 TTO 值为零(这将导致未定义的值)的情况。TTO 值按每年 3%贴现。在修剪了前 2.5%和后 2.5%的响应后,计算了 WTP 每 QALY 的平均值。使用假设负二项分布的广义线性混合模型进行了多变量分析。

结果

在所有受访者中,每 QALY 的 WTP 范围从中位数 7000 美元到 11000 美元,修剪后的平均值从 26000 美元到 45000 美元不等(2005 年的美元价值),这取决于描述的情景。WTP 每 QALY 值因受访者特征以及具有相似特征的受访者之间的差异而显著不同。在多变量分析中,年龄较小、男性或受教育程度或收入水平较高的受访者的平均 WTP 每 QALY 值较高。在调整了这些人口统计学变量后,经历过带状疱疹的患者的 WTP 每 QALY 值最高。经历过 PHN 的患者的 WTP 每 QALY 值最低,社区成员的 WTP 每 QALY 值介于带状疱疹和 PHN 组之间。在评估假设带状疱疹情景的疼痛和持续时间影响的多变量模型中,较短的持续时间与较高的 WTP 每 QALY 值相关。这种效应似乎是由于人们随着持续时间的增加而增加愿意交换的时间量,而不是随着他们愿意支付的金额的增加而按比例增加。

结论

社区成员和患者的 WTP 每 QALY 值差异很大,这取决于年龄、性别、社会经济地位、带状疱疹的经验和所评估的健康状况的持续时间。WTP 每 QALY 的变异性表明,基于成本效益分析制定政策可能很难定义一个统一的美元/QALY 阈值。

相似文献

1
Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.社区成员和患者对与带状疱疹相关的临时健康状态的偏好为基础的 QALY 的支付意愿。
Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000.
2
Community and patient values for preventing herpes zoster.预防带状疱疹的社区和患者价值观。
Pharmacoeconomics. 2008;26(3):235-49. doi: 10.2165/00019053-200826030-00006.
3
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.在美国对一种预防老年人带状疱疹和带状疱疹后神经痛的疫苗进行成本效益评估。
Vaccine. 2007 Nov 28;25(49):8326-37. doi: 10.1016/j.vaccine.2007.09.066. Epub 2007 Oct 17.
4
Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.德国预防带状疱疹和疱疹后神经痛的疫苗接种策略的健康经济评价。
BMC Health Serv Res. 2013 Sep 26;13:359. doi: 10.1186/1472-6963-13-359.
5
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.非活佐剂重组带状疱疹疫苗对加拿大成年人的公共卫生影响和成本效益。
Appl Health Econ Health Policy. 2019 Oct;17(5):723-732. doi: 10.1007/s40258-019-00491-6.
6
Cost effectiveness of herpes zoster vaccine in Canada.加拿大带状疱疹疫苗的成本效益。
Pharmacoeconomics. 2009;27(12):991-1004. doi: 10.2165/11314010-000000000-00000.
7
Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.带状疱疹疫苗对 50 岁人群的成本效益分析
Ann Intern Med. 2015 Oct 6;163(7):489-97. doi: 10.7326/M15-0093.
8
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.一种预防老年人带状疱疹和带状疱疹后神经痛疫苗的成本效益
Clin Infect Dis. 2007 May 15;44(10):1280-8. doi: 10.1086/514342. Epub 2007 Apr 3.
9
Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.在比利时,成人带状疱疹(带状疱疹)和疱疹后神经痛预防疫苗的健康经济评价。
J Med Econ. 2010;13(3):537-51. doi: 10.3111/13696998.2010.502854.
10
Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.对基础胰岛素相关属性改善的偏好:瑞典糖尿病和非糖尿病患者群体的时间权衡与支付意愿调查
J Med Econ. 2016 Oct;19(10):945-58. doi: 10.1080/13696998.2016.1187152. Epub 2016 May 31.

引用本文的文献

1
Willingness to pay for HIV pre- and post-exposure prophylaxis services delivered via an online pharmacy in Kenya.肯尼亚通过在线药房提供的艾滋病毒暴露前和暴露后预防服务的支付意愿。
BMC Health Serv Res. 2025 Apr 22;25(1):576. doi: 10.1186/s12913-025-12766-x.
2
Prediction of COVID-19 patients' participation in financing informal care using machine learning methods: willingness to pay and willingness to accept approaches.使用机器学习方法预测 COVID-19 患者参与非正式护理的意愿:支付意愿和接受意愿方法。
BMC Health Serv Res. 2024 Jul 10;24(1):796. doi: 10.1186/s12913-024-11250-2.
3
A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries.

本文引用的文献

1
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.评估医疗保健中的成本效益:50,000 美元/QALY 阈值的历史。
Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165-78. doi: 10.1586/14737167.8.2.165.
2
Importance of preference reversals in the valuation of health and healthcare.偏好逆转在健康和医疗保健估值中的重要性。
Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):95-9. doi: 10.1586/14737167.8.2.95.
3
Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).
一项关于直接 elicitation 需求方成本效益阈值的系统评价:对低收入和中等收入国家的启示。
PLoS One. 2024 Feb 8;19(2):e0297450. doi: 10.1371/journal.pone.0297450. eCollection 2024.
4
Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.在中国建立成本效益阈值:一项关于健康生活年支付意愿的社区调查。
BMJ Glob Health. 2024 Jan 9;9(1):e013070. doi: 10.1136/bmjgh-2023-013070.
5
Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries.插队:七个欧洲国家对更快获得 COVID-19 疫苗的支付意愿。
Pharmacoeconomics. 2023 Oct;41(10):1389-1402. doi: 10.1007/s40273-023-01284-5. Epub 2023 Jun 21.
6
Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.基于支付意愿和人均 GDP 估算医疗保健增量成本效益阈值范围:系统评价。
PLoS One. 2022 Apr 14;17(4):e0266934. doi: 10.1371/journal.pone.0266934. eCollection 2022.
7
Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60.60岁及以上成人带状疱疹疫苗的费用分担要求。
J Pharm Technol. 2019 Dec;35(6):258-269. doi: 10.1177/8755122519860074. Epub 2019 Jul 3.
8
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines.加拿大胃肠病学协会炎症性肠病(IBD)患者免疫接种临床实践指南 - 第2部分:灭活疫苗
J Can Assoc Gastroenterol. 2021 Jul 29;4(4):e72-e91. doi: 10.1093/jcag/gwab016. eCollection 2021 Aug.
9
Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.支付意愿以获得质量调整生命年:系统综述和荟萃回归分析。
Eur J Health Econ. 2022 Mar;23(2):277-299. doi: 10.1007/s10198-021-01364-3. Epub 2021 Aug 21.
10
Comparing the monetary value of a quality-adjusted life year from the payment card and the open-ended format.比较支付卡法和开放式格式下质量调整生命年的货币价值。
Cost Eff Resour Alloc. 2021 Jul 19;19(1):45. doi: 10.1186/s12962-021-00298-0.
带状疱疹的预防:免疫实践咨询委员会(ACIP)的建议。
MMWR Recomm Rep. 2008 Jun 6;57(RR-5):1-30; quiz CE2-4.
4
What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?现代医学的价值对于每质量调整生命年5万美元的决策规则有何看法?
Med Care. 2008 Apr;46(4):349-56. doi: 10.1097/MLR.0b013e31815c31a7.
5
How much are Americans willing to pay for a quality-adjusted life year?美国人愿意为一个质量调整生命年支付多少钱?
Med Care. 2008 Apr;46(4):343-5. doi: 10.1097/MLR.0b013e31816a7144.
6
Community and patient values for preventing herpes zoster.预防带状疱疹的社区和患者价值观。
Pharmacoeconomics. 2008;26(3):235-49. doi: 10.2165/00019053-200826030-00006.
7
Does preventive care save money? Health economics and the presidential candidates.预防性医疗保健能省钱吗?健康经济学与总统候选人。
N Engl J Med. 2008 Feb 14;358(7):661-3. doi: 10.1056/NEJMp0708558.
8
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.在美国对一种预防老年人带状疱疹和带状疱疹后神经痛的疫苗进行成本效益评估。
Vaccine. 2007 Nov 28;25(49):8326-37. doi: 10.1016/j.vaccine.2007.09.066. Epub 2007 Oct 17.
9
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.一种预防老年人带状疱疹和带状疱疹后神经痛疫苗的成本效益
Clin Infect Dis. 2007 May 15;44(10):1280-8. doi: 10.1086/514342. Epub 2007 Apr 3.
10
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.一种预防老年人带状疱疹和带状疱疹后神经痛疫苗的成本效益
Ann Intern Med. 2006 Sep 5;145(5):317-25. doi: 10.7326/0003-4819-145-5-200609050-00004.